Treatment
There is no cure. Early hospital care saves lives.
No antiviral drug has been proven effective against hantavirus pulmonary syndrome. Treatment is entirely supportive, focused on maintaining breathing and circulation until the immune system clears the virus.
Why early action matters
The median time from symptom onset to death in fatal HPS cases is just 3 to 7 days. Patients who reach an ICU before severe respiratory distress have survival rates above 60%. Those who delay often face mortality rates exceeding 50%. If you suspect hantavirus exposure and develop fever with breathing difficulty, go to an emergency room immediately.
Standard ICU treatment protocol
Early ICU admission
CriticalThe single most important factor in survival. Patients admitted to intensive care within 24 hours of respiratory symptoms have significantly better outcomes. HPS can progress from mild cough to respiratory failure in under 12 hours.
Oxygen therapy
CriticalSupplemental oxygen is the first line of treatment. As the lungs fill with fluid, maintaining blood oxygen saturation becomes the primary challenge. Mechanical ventilation is required in most severe cases.
Fluid management
CriticalCareful IV fluid balance is essential. Unlike most shock conditions, aggressive fluid resuscitation can worsen pulmonary edema in HPS. Clinicians must balance circulation support with lung protection.
ECMO (Extracorporeal membrane oxygenation)
For the most severe cases, ECMO acts as an external lung, oxygenating blood outside the body. Studies show ECMO can reduce mortality from 100% to roughly 40% in patients who would otherwise die. Available only at specialized centers.
Vasopressors
Medications to maintain blood pressure when the cardiovascular system fails. Norepinephrine and dobutamine are commonly used. Required when cardiac output drops dangerously low.
Experimental treatments
Ribavirin
Limited evidenceAn antiviral that showed early promise against Old World hantaviruses (HFRS) but has not demonstrated clear benefit against New World strains causing HPS. The CDC does not currently recommend it for HPS treatment.
Favipiravir
Under investigationA broad-spectrum antiviral being studied for potential activity against hantaviruses. Animal studies show some promise, but no human clinical trials have confirmed effectiveness against HPS.
Immunotherapy / convalescent plasma
ExperimentalPlasma from recovered hantavirus patients contains antibodies that may help fight the virus. Small studies suggest a possible benefit, but large-scale trials are lacking.
Frequently asked questions about hantavirus treatment
Can antibiotics cure hantavirus?
No. Hantavirus is a virus, not a bacteria. Antibiotics have no effect. There is no antiviral drug proven to work against HPS.
How long does treatment take?
Survivors typically spend 1 to 3 weeks in the ICU. Full recovery can take months as lung function gradually returns. Some patients experience lasting fatigue and reduced exercise tolerance.
What is the survival rate with treatment?
With modern ICU care, the survival rate for HPS is approximately 60 to 65%. Without intensive care, mortality exceeds 50%. Early admission is the strongest predictor of survival.
Can you recover from hantavirus at home?
HPS cannot be safely managed at home. The rapid onset of respiratory failure requires mechanical ventilation and constant monitoring. Mild cases of HFRS (the hemorrhagic form, found mainly in Asia/Europe) may be managed with hospital observation.